Rebel Medicine Secures Series A Funding and IND Application for Non-Opioid Pain Therapy Development

Rebel Medicine Inc, a biotechnology company based in Salt Lake City, Utah, has successfully raised $6 million through a Series A financing round. This funding round was led by Crocker Ventures and saw participation from various investors including the Central Texas Angel Network (CTAN), Prosperity Solutions Capital, Utah Innovation Fund, SK Hart, the Joan & Tim Fenton Fund, Cantina Angels, and a group of seasoned angel investors specializing in life sciences. This financial achievement aligns with the company's progress in filing an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for Alevatrix™, their lead non-opioid pain medication candidate.

The newly acquired funds are earmarked for conducting a Phase 2 clinical trial, focusing on bunionectomy patients. This trial will be a randomized, dose-escalation, active-controlled study aimed at evaluating the safety and effectiveness of Alevatrix™. Brett Davis, PhD, Co-Founder and CEO of Rebel Medicine, expressed that this milestone is a pivotal point for the company. He emphasized that the completion of the Series A funding round confirms the company's strategic vision and the promising potential of its technological innovations. The IND clearance for Alevatrix™ further facilitates the acceleration of its clinical development, ultimately aiming to deliver opioid-sparing pain relief solutions to patients more efficiently.

Alevatrix™ is an innovative, long-acting form of bupivacaine, a widely recognized local anesthetic, which is encapsulated in Rebel Medicine's unique injectable matrix. This design is intended to release the medication at the site of administration for up to 72 hours, therefore aiming to minimize or remove the necessity for opioids post-surgery and mitigate their associated risks. In preclinical investigations, Alevatrix™ demonstrated an ability to provide prolonged, multi-day non-opioid pain relief while maintaining a favorable safety profile.

Rebel Medicine Inc is a privately owned biotechnology firm that harnesses its proprietary drug delivery technology to improve the functionality of validated pharmaceutical ingredients. The company's approach results in innovative, high-value, extended-release therapeutics that address pressing unmet clinical needs, all while reducing the time, cost, and risk associated with development. Alevatrix™ is the company's leading asset, specifically designed for non-opioid post-operative pain management. Additionally, Rebel Medicine is working on other pipeline programs that utilize its proprietary delivery systems to extend the release of injectable drugs from a few days to several months.

This significant advancement for Rebel Medicine not only highlights the progress made in developing Alevatrix™ but also marks a major step towards addressing the global need for effective non-opioid pain management solutions. Rebel Medicine's innovative approach and strategic financial backing position it well to make a substantial impact in the field of pain therapeutics.